This study investigated the expression and clinicopathological significance of CD9 in gastrointestinal stromal tumor (GIST). Immunohistochemistry staining for CD9 was performed on tumor tissues from 74 GIST patients. The correlation with clinicopathological features, risk classification and prognosis was analyzed. CD9-positive staining comprised 59.5% (44/74) of the GIST patients. The CD9-positive expression rate of the sample was significantly associated with diameter (P = 0.028), mitotic counts (P = 0.035), risk classification (P = 0.018) and three-year recurrence-free survival (RFS) (P < 0.001). Cox proportional hazards regression (HR = 0.352; P = 0.015) showed that CD9 is an independent factor for post-operative RFS. The subgroup analysis showed that CD9 expression in gastric stromal tumor (GST) is significantly associated with diameter (P = 0.031), risk classification (P = 0.023) and three-year RFS (P = 0.001). The Cox proportional hazards regression (HR = 0.104; P = 0.006) also showed that CD9 is an independent factor for RFS of GST. However, CD9 expression does not have a statistically significant correlation with clinicopathological features, risk classification, and prognosis in non-GST. In conclusion, CD9 expression in GIST appears to be associated with the recurrence and/or metastasis of GIST patients, especially in GST, which may indicate the important role of CD9 in the malignant biological behavior and prognosis of GST.
INTRODUCTION
Knowledge on the etiology, pathogenesis, diagnosis and treat ment of gastrointestinal stromal tumors (GIST) have reached maturity in recent years. GIST prognosis has been also improv ed significantly. However, the reason that only certain parts of GIST patients relapse or metastasize after operation in the same site remains unclear. Moreover, nongastric stromal tumor (GST), intestinal and extragastrointestinal stromal tumor (EGIST) re lapses or metastasizes more easily than GST, even with the same diameter and mitotic counts, which is a phenomenon that should be explored (1) . Although metastasis mainly spreads through blood and implantation metastasis in GIST, the mechanism of metastasis remains unclear, and current studies on the mecha nism of metastasis in GIST are limited.
CD9 protein that belongs to the transmembrane 4 superfam ily (TM4SF) is a transmembrane glycoprotein. This protein is present in various tumors, which indicates that CD9 expression is inversely correlated with recurrence and/or metastasis, and can be utilized as a prognostic marker (2, 3) .
This study investigates CD9 expression in GIST and analyzes its correlation with clinicopathological significance, risk classi fication and prognosis.
MATERIALS AND METHODS

Patients and tissue samples
Surgical samples were selected from West China Hospital, Sich uan University of China between January 2002 and June 2010. The following inclusion criteria were used: pathologically con firmed negative surgical margins (R0) after resection, immuno histochemically confirmed CD117positive tumor; no preop erative imatinib mesylate (IM) treatment; no severe systemic disease or combined tumor. The exclusion criteria were as fol lows: less than 18 yr of age; pregnant or breastfeeding patients; with severe systemic disease or combined tumor; and poor compliance.
Immunohistochemistry
Immunohistochemical staining was performed on 4 μm paraf fin sections. The sections were soaked through water washing and then incubated in 3% H2O2 methanol solution for 10 min. Soaked in 0.01 M/L EDTA (pH = 9.0) and repaired in a separated water environment for 10 min through pressure heating. Then, blocked with goat serum for 20 min at room temperature. Rab bit monoclonal CD9 antibody (purchased from Abcam Ltd., Cam bridge, UK) was applied overnight with a dilution of 1:300 at 4°C and incubated for 30 min with biotinylated goat antimouse im munoglobulin G. The sections was detected with a secondary antibody for 30 min at room temperature and visualized through incubation by using DAB (1:50 dilution) for 5 min to 10 min. The sections was then counterstained, dehydrated and mounted.
The stained specimens were reviewed by two pathologists who had no knowledge of the clinical status of the patients. The sections were scored semiquantitatively based on previously described method (4), which considered cell staining intensity and percentage. Intensities were classified as 0 (no staining), 1 (weak staining), 2 (distinct staining), and 3 (very strong stain ing). The cell staining percentage as classified as 0 ( < 10%), 1 (10% to 25%), 2 (26% to 50%), 3 (51% to 75%) and 4 ( > 75%). The total score for each specimen was calculated by using the following equation: total score = score of intensity multiplied by score of percentage. Specimens with a total score > 3 were classified as CD9positive (+), whereas specimens with total score ≤ 3 were classified as CD9negative ().
Data and statistical analysis
The last followup was conducted on December 31, 2012. Re currencefree survival (RFS) is the date of operation to the date of recurrence and/or distant metastasis, which is the endpoint for GIST patients. Patients who survived without recurrence and/or metastasis were censored on the date of the last follow up. The data were evaluated by using SPSS version 18.0. Mea surement data were expressed as mean ± standard deviation. Categorical data from different groups were compared by using the chisquare test or Fisher's exact test. Cumulative RFS was estimated by using the Kaplan-Meier method with a onesided logrank test. Hazard regression model and 95% confidence in terval (CI) were described based on the Cox proportion HR mo del. P < 0.05 was considered statistically significant.
Ethics statement
The study protocol was approved by the institutional review board of West China Hospital, Sichuan University, China (No. 201364), and an informed consent was obtained from every of the patients.
RESULTS
Characteristics of the patients A total of 74 patients included 50 males and 24 females, with a mean age of 52.9 ± 12.2 (from 29 to 84) yr. The pathological types included 38 GST, 23 intestinal GIST, and 13 EGIST. Based on The NCCN guideline for risk classification of GIST (5), 10 tu mors were low risk, 11 were intermediate risk, and 53 were high risk. Fig. 1A shows that the immunohistochemical positive reaction product of CD9 was mainly localized in the cytoplasm and/or cell membrane. About 59.5% (44/74) of the 74 GIST specimens were classified as CD9positive. By contrast, 40.5% (30/74) were classified as CD9negative (Fig. 1B) . Table 1 summarizes the immunoreactivities in GIST. No sig nificant association was observed between CD9 expression and age (P = 0.333), sex (P = 0.712), and location (P = 0.769) when CD9 expression was compared with various clinical features. However, a highly significant association was found between CD9 expression and tumor diameter (P = 0.028), mitotic count (P = 0.035), and risk classification (P = 0.018).
CD9 expression in GIST and the relationship between CD9 expression and clinicopathological features of GIST
Relationship between CD9 expression and RFS
The 74 patients were followed up regularly through telephone and outpatient visits. The average followup time was 49 months (6 to132 months). 9 patients recurred, 16 patients had a distant metastasis, 5 patients recurred and merging with a distant me tastasis. After excluding seven patients who received IM treat ment postoperation and three who underwent a followup time of < three years postoperation, sixtyfour patients left, who underwent at least 36 months of followup without post operative IM adjuvant treatment. In the 64 patients, the three year RFS rate was 78.4% (29/37) in 37 patients with CD9posi tive expression compared with 33.3% (9/27) in 27 patients with CD9negative expression (P < 0.001). The Cox proportion haz ards regression (HR, 0.352; 95% CI: 0.153 to 0.813; P = 0.015) showed that CD9 expression is an independent prognostic fac tor of RFS. The cumulative RFS curve of 64 patients in relation to CD9 expression showed that the CDpositive group has a sig nificantly better cumulative RFS rate compared with the group with CD9negative expression (P = 0.015) (Fig. 2) .
The relationship of CD9 expression in GST with clinicopathological features, risk classification and RFS Table 2 shows the lack of significant association between CD9 expression and age (P = 0.578), sex (P = 0.542), and mitotic 2 . Kaplan-Meier estimates of RFS between CD9-positive GIST and CD9-negative GIST group. The hazard ratio for RFS in the CD9-positive group was 0.352 (95% CI, 0.153 to 0.813; P = 0.015) compared with the CD9-negative group. RFS curves were constructed using the Kaplan-Meier method. Differences between the curves were tested for statistical significance using Log-rank statistics. count (P = 0.645) in the 38 GSTs. However, a highly significant association was observed between CD9 expression and tumor diameter (P = 0.031) and risk classification (P = 0.023).
Recurrence-free survival
Two patients who received IM treatment postoperation and three patients who underwent a followup time of < three years postoperation were excluded. The threeyear RFS rate of the http://dx.doi.org/10.3346/jkms.2013.28.10.1443 remaining 33 patients was 88.9% (16/18) in 18 patients with CD9positive expression compared with 33.3% (5/15) in 15 pa tients with CD9negative expression (P = 0.001). The Cox pro portion hazards regression (HR, 0.104; 95% CI: 0.021 to 0.528; P = 0.006) showed that CD9 expression was also an indepen dent prognostic factor of RFS for GST. The cumulative RFS curve showed that the RFS of patients with CDpositive expression group was significantly better than that of the CD9negative ex pression group (P = 0.006) (Fig. 3) .
The relationship of CD9 expression in non-GST with clinicopathological features, risk classification and RFS
No significant relationship was observed between CD9 expres sion and clinicopathological features, risk classification, and operative threeyear RFS (P > 0.05) of the 36 nonGST patients. The Cox proportion hazards regression (HR, 0.710; 95% CI: 0.214 to 2.353; P = 0.575) showed that CD9 expression was not an in dependent prognostic factor.
DISCUSSION
Despite complete resection, nearly half of the primary GIST re curred or had a metastasis, and showed poor outcome (6) . Jo ensuu found that nonGST relapsed or metastasized more easi ly than GST even with the same diameter and mitotic count. However, the reason behind this phenomenon remains unclear because the mechanism is yet to be classified. IM has significantly improved the prognosis of advanced or highrisk GIST patients (7). However, secondary resistance caus ed by gene amplification or secondary gene mutation caused by prolonged IM treatment has became the main factor that af fects prognosis (8) . An indepth study of the mechanism of re currence and/or metastasis may screen patients with high risk of recurrence or metastasis postoperation and provide a basis for implementing individualized treatment to improve prognosis.
Tumor recurrence and/or metastasis is a complex process accompanied with multiple genes and regulated by the interac tion of a number of genes, adhesion molecules, enzymes, and protein. Epigenetic changes occur in small GISTs, such as 14q, 15q, and 22q, which result in malignant transformation and metastasis (911). Okamoto et al. (12) found that the methyla tive level of tumor suppressor genes, such as RASSF1A, P1, CDH1, and MGMT4, is correlated with tumor malignancy. Thus, this study examined whether some proteins play important roles in the mechanism of recurrence and/or metastasis in GIST.
CD9, which belongs to TM4SF, can inhibit proliferation and metastasis by inhibiting the activation of the Wnt signaling path way (13) , the degradation of transforming growth factor α (TGFα) (14) , and the secretion of metalloproteinase (15) . CD9 down regulation is a poor prognostic marker in various cancers and is correlated with tumor invasion and metastasis in gastric cancer (16) , lung cancer (17) , and bladder cancer (18) . Setoguchi et al. (19) found that CD9 in metastatic liver GIST is downregulated by microarray and PCR. The present study employed immu nohistochemistry analysis in detecting CD9 expression to in vestigate its correlation with clinicopathological features, risk classification, and prognosis.
In our study, fortyfour (59.5%) cases are CD9 positive. Posi tive reaction product was mainly localized in the cytoplasm and/or cell membrane, similar to other reports (20, 21) . The positive rates of CD9 were higher in cases with ≤ 5 cm diame ter, ≤ 10/50 HPF mitotic count, and low/intermediaterisk group than in cases with > 5 cm diameter, > 10/50 HPF mitotic counts, and highrisk group (P < 0.05). These results suggest that reduced CD9 expression plays an important role in tumor progression and malignant behaviors. Comparing the RFS of CD9positive with CD9negative group, the universal analysis showed that the postoperative threeyear RFS rate of the CD9 positive group is higher than that of the CD9negative group (78.4% vs 33.3%, P < 0.001). Multivariate analysis (HR, 0.352; 95% CI, 0.153 to 0.813; P = 0.015) showed that CD9 expression is an independent predictor of RFS. It indicates CD9 is an im portant role in the invasion process and metastasis in GIST, the loss of CD9 increases the risk of recurrence or metastasis. Thus, CD9 may be a favorable predictor of tumor progression or ag gressive behavior in GIST.
Researchers are increasingly focusing on the role of CD9 in recurrence or metastasis of GIST. Setoguchi et al. (19) confirm Fig. 3 . Kaplan-Meier estimates of RFS between CD9-positive GST and CD9-negative GST group. The hazard ratio for RFS in the CD9-positive group was 0.104 (95% CI, 0.021 to 0.528; P = 0.006) compared with the CD9-negative group. RFS curves were constructed using the Kaplan-Meier method. Differences between the curves were tested for statistical significance using Log-rank statistics. ed that the postoperative fiveyear RFS rate of the CD9positive group is higher than that of the CD9negative group in GST. However, a statistically significant relationship was not found between these two groups in intestinal GIST. This finding is at tributed to the different functions and signal transduction path ways in different organs (22) .In our study, the subgroup analy sis of GST in this study showed that the positive rate of CD9 ex pression of the ≤ 5 cm group is higher than that of the > 5 cm group (P = 0.031). The CD9positive rate declined when risk in creased (P = 0.023). The postoperative threeyear rate of the CD9positive group was higher than that of the CD9negative group (88.9% vs 33.3%, P = 0.001). However, no significant dif ference was found between CD9 expression and clinicopatho logical features risk classification and RFS in nonGST. This finding is consistent with the findings of Setoguchi. Thus, un like nonGST, it indicates that CD9 expression may be organ specific, CD9 plays an more important role in the progression and/or metastasis of GST.
In conclusion, CD9 expression is closely related to the diam eter, risk classification, and RFS of GIST, especially in GST. CD9 expression is downregulated during the malignant transforma tion process or metastasis in GST. This mechanism of CD9 could be a potential prognostic marker in GST and may guide indi vidualized treatment for patients.
